450 related articles for article (PubMed ID: 29682504)
61. Benralizumab as a potential treatment of asthma.
Antoniu SA
Expert Opin Biol Ther; 2017 Jul; 17(7):895-900. PubMed ID: 28406319
[TBL] [Abstract][Full Text] [Related]
62. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials.
Tian BP; Zhang GS; Lou J; Zhou HB; Cui W
J Asthma; 2018 Sep; 55(9):956-965. PubMed ID: 29211545
[TBL] [Abstract][Full Text] [Related]
63. Interleukin-13 in Asthma and Other Eosinophilic Disorders.
Doran E; Cai F; Holweg CTJ; Wong K; Brumm J; Arron JR
Front Med (Lausanne); 2017; 4():139. PubMed ID: 29034234
[TBL] [Abstract][Full Text] [Related]
64. Successful treatment of eosinophilic chronic rhinosinusitis and eosinophilic otitis media using the anti-IL-5 receptor monoclonal antibody benralizumab: A case report.
Kagoshima H; Hori R; Kojima T; Okanoue Y; Taguchi A; Yamamoto H; Hasebe K; Shoji K
Respir Med Case Rep; 2020; 30():101135. PubMed ID: 32612919
[TBL] [Abstract][Full Text] [Related]
65. Urine eosinophil-derived neurotoxin: A potential marker of activity in select eosinophilic disorders.
Makiya MA; Khoury P; Kuang FL; Mata AD; Mahmood S; Bowman A; Espinoza D; Kovacs N; Brown T; Holland N; Wetzler L; Ware JM; Dyer AM; Akuthota P; Bochner BS; Chinchilli VM; Gleich GJ; Langford C; Merkel PA; Specks U; Weller PF; Wechsler ME; Prussin C; Fay MP; Klion AD
Allergy; 2023 Jan; 78(1):258-269. PubMed ID: 35971862
[TBL] [Abstract][Full Text] [Related]
66. Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma.
Kupczyk M; Kuna P
Immunotherapy; 2018 Apr; 10(5):349-359. PubMed ID: 29359607
[TBL] [Abstract][Full Text] [Related]
67. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
Simon D; Braathen LR; Simon HU
Pathobiology; 2005; 72(6):287-92. PubMed ID: 16582580
[TBL] [Abstract][Full Text] [Related]
68. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics.
Menzies-Gow A; Flood-Page P; Sehmi R; Burman J; Hamid Q; Robinson DS; Kay AB; Denburg J
J Allergy Clin Immunol; 2003 Apr; 111(4):714-9. PubMed ID: 12704348
[TBL] [Abstract][Full Text] [Related]
69. Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations.
Bagnasco D; Ferrando M; Caminati M; Bragantini A; Puggioni F; Varricchi G; Passalacqua G; Canonica GW
Drug Saf; 2017 Jul; 40(7):559-570. PubMed ID: 28321782
[TBL] [Abstract][Full Text] [Related]
70. Expression of eosinophil β chain-signaling cytokines receptors, outer-membrane integrins, and type 2 inflammation biomarkers in severe non-allergic eosinophilic asthma.
Kalinauskaite-Zukauske V; Januskevicius A; Janulaityte I; Miliauskas S; Malakauskas K
BMC Pulm Med; 2019 Aug; 19(1):158. PubMed ID: 31438916
[TBL] [Abstract][Full Text] [Related]
71. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
Praxis (Bern 1994); 2019; 108(7):1-8. PubMed ID: 31136278
[TBL] [Abstract][Full Text] [Related]
72. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M
Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852
[TBL] [Abstract][Full Text] [Related]
73. New Targeted Therapies for Uncontrolled Asthma.
Corren J
J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
[TBL] [Abstract][Full Text] [Related]
74. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
[TBL] [Abstract][Full Text] [Related]
75. Development of a robust reporter gene based assay for the bioactivity determination of IL-5-targeted therapeutic antibodies.
Fu Z; Yu C; Wang L; Gao K; Xu G; Wang W; Cao J; Wang J
J Pharm Biomed Anal; 2018 Jan; 148():280-287. PubMed ID: 29059618
[TBL] [Abstract][Full Text] [Related]
76. Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.
Zhang C; Wang Y; Zhang M; Su X; Lei T; Yu H; Liu J
Front Pharmacol; 2021; 12():754268. PubMed ID: 34795588
[No Abstract] [Full Text] [Related]
77. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
Praxis (Bern 1994); 2019; 108(7):469-476. PubMed ID: 31136272
[TBL] [Abstract][Full Text] [Related]
78. Eosinophils and eosinophilic immune dysfunction in health and disease.
Jackson DJ; Akuthota P; Roufosse F
Eur Respir Rev; 2022 Mar; 31(163):. PubMed ID: 35082127
[TBL] [Abstract][Full Text] [Related]
79. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
[TBL] [Abstract][Full Text] [Related]
80. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
